• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Preparation and characterization of human HIV type 1 neutralizing reference sera.

作者信息

Vujcic L K, Quinnan G V

机构信息

Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852-1448, USA.

出版信息

AIDS Res Hum Retroviruses. 1995 Jul;11(7):783-7. doi: 10.1089/aid.1995.11.783.

DOI:10.1089/aid.1995.11.783
PMID:7546904
Abstract

Reference neutralizing antibody (NA) reagents are needed for laboratories to be able to compare results of neutralization assays that will be used to monitor HIV-1 vaccine recipients. In an effort to establish such reference reagents two asymptomatic, seropositive patients were identified with medium to high amounts of cross-reactive NA activity against a number of HIV-1 strains. Sera obtained from each individual at three or four sequential phlebotomies were pooled, and the two pools were each distributed in > 3000 aliquots into glass ampoules and lyophilized, and the ampoules were flame sealed. An HIV-1 antibody-negative reference serum was prepared in a similar fashion after pooling serum from four individuals. Ampoules were tested for uniformity of fill, sterility, moisture content, residual oxygen, stability, infectivity, and presence of antibody. An international collaborative study was conducted to determine the potency of the samples in six laboratories, each using their own neutralization assays and reagents. The results indicated reasonable consistency between laboratories and that both sera have sufficient titers against a variety of strains for use as reference reagents. These reference sera have been included in the World Health Organization (WHO) AIDS Reagent Project and are available through the three AIDS reagent repositories.

摘要

相似文献

1
Preparation and characterization of human HIV type 1 neutralizing reference sera.
AIDS Res Hum Retroviruses. 1995 Jul;11(7):783-7. doi: 10.1089/aid.1995.11.783.
2
International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus.
AIDS Res Hum Retroviruses. 1990 Jul;6(7):847-53. doi: 10.1089/aid.1990.6.847.
3
High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.非洲和美洲血清中针对HIV-1MN主要中和决定簇gp120 V3区域的抗体高流行率。
AIDS Res Hum Retroviruses. 1991 Oct;7(10):831-8. doi: 10.1089/aid.1991.7.831.
4
Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.与抗I型人类免疫缺陷病毒的抗体依赖性细胞毒性诱导抗体相关的中和抗体。
Clin Exp Immunol. 1988 Sep;73(3):339-42.
5
Evaluation of efficacy of pooled sera in a human immunodeficiency virus antibody prevalence in population surveys.群体调查中混合血清在人类免疫缺陷病毒抗体流行率检测中的效能评估。
Rev Roum Virol. 1990 Jan-Mar;41(1):45-51.
6
Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.由HIV-1感染患者腮腺IgA介导的1型人类免疫缺陷病毒(HIV-1)中和作用。
J Infect Dis. 2000 May;181(5):1607-13. doi: 10.1086/315420. Epub 2000 May 8.
7
Comparison of two serological tests for the identification of recent HIV infection: Vironostika HIV-1 Microelisa and BED capture enzyme immunoassay.两种用于识别近期HIV感染的血清学检测方法的比较:Vironostika HIV-1微酶免疫测定法和BED捕获酶免疫测定法。
Enferm Infecc Microbiol Clin. 2011 Aug-Sep;29(7):553-5. doi: 10.1016/j.eimc.2011.02.016. Epub 2011 Apr 17.
8
Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells.开发和优化基于假病毒的敏感检测方法,用于检测 HIV-1 中和抗体,使用 A3R5 细胞。
Hum Vaccin Immunother. 2018 Jan 2;14(1):199-208. doi: 10.1080/21645515.2017.1373922. Epub 2017 Oct 18.
9
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.1型人类免疫缺陷病毒感染个体初次血清转化后的自体和异体中和抗体反应。
J Virol. 1997 May;71(5):3734-41. doi: 10.1128/JVI.71.5.3734-3741.1997.
10
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.1型人类免疫缺陷病毒ADA株gp120单体与gp140三聚体作为诱导中和抗体免疫原的比较
AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67. doi: 10.1089/aid.2005.21.58.

引用本文的文献

1
HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.采用 Env 介导的膜融合试验测定 eCD4-Igmim2 对 HIV-1 的抑制特性。
PLoS One. 2018 Oct 25;13(10):e0206365. doi: 10.1371/journal.pone.0206365. eCollection 2018.
2
Tetherin Antagonism by HIV-1 Group M Nef Proteins.HIV-1 M组Nef蛋白对 tetherin 的拮抗作用
J Virol. 2016 Nov 14;90(23):10701-10714. doi: 10.1128/JVI.01465-16. Print 2016 Dec 1.
3
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
通过靶向包膜跨膜亚基gp41抑制HIV进入
Curr HIV Res. 2016;14(3):283-94. doi: 10.2174/1570162x14999160224103908.
4
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.Vpu 通过拮抗 tetherin 保护感染 HIV 的细胞免受抗体依赖的细胞介导的细胞毒性作用。
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6425-30. doi: 10.1073/pnas.1321507111. Epub 2014 Apr 14.
5
Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.源自一名精英中和者的可溶性HIV-1包膜免疫原可引发交叉反应性V1V2抗体和低效中和抗体。
PLoS One. 2014 Jan 23;9(1):e86905. doi: 10.1371/journal.pone.0086905. eCollection 2014.
6
Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.亚抑制浓度的人α-防御素增强了血清存在下针对 HIV-1 gp41 发夹前中间体的中和抗体。
PLoS Pathog. 2013;9(6):e1003431. doi: 10.1371/journal.ppat.1003431. Epub 2013 Jun 13.
7
Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins.人类免疫缺陷病毒 1 型单价或三价包膜糖蛋白诱导的猕猴中和抗体反应。
PLoS One. 2013;8(3):e59803. doi: 10.1371/journal.pone.0059803. Epub 2013 Mar 22.
8
Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04.HIV-1 gp120 的外域:抗原优化、结构可塑性,以及与抗体 VRC-PG04 的晶体结构。
J Virol. 2013 Feb;87(4):2294-306. doi: 10.1128/JVI.02717-12. Epub 2012 Dec 12.
9
Human CRM1 augments production of infectious human and feline immunodeficiency viruses from murine cells.人 CRM1 增强了从鼠细胞中产生传染性的人免疫缺陷病毒和猫免疫缺陷病毒。
J Virol. 2012 Nov;86(22):12053-68. doi: 10.1128/JVI.01970-12. Epub 2012 Aug 29.
10
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.广谱中和抗体为应对高度抗原多样化的病毒带来了新的前景。
Science. 2012 Jul 13;337(6091):183-6. doi: 10.1126/science.1225416.